Company Encyclopedia
View More
name
BIOTEST BIOTECH
688767.SH
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits.
1.601 T
688767.SHMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking42/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.35%C
    • Profit Margin21.43%A
    • Gross Margin46.02%B
  • Growth ScoreD
    • Revenue YoY-7.70%D
    • Net Profit YoY-1.65%C
    • Total Assets YoY-2.16%D
    • Net Assets YoY-1.62%D
  • Cash ScoreD
    • Cash Flow Margin466.71%C
    • OCF YoY-7.70%D
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreA
    • Gearing Ratio5.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Multiple A-share companies reveal progress and product updates in brain-computer interface technology

    In a recent earnings briefing, several A-share listed companies, including Xiangyu Medical, MEDLANDER, BIOTEST BIOTECH, and ZKTECO, disclosed the latest developments in brain-computer interface technology. Some companies expect to achieve revenue within the year, launch new products, and seize development opportunities through investment layouts. In the second half of the year, relevant companies will accelerate investment and product implementation, and local policies will also support commercialization, driving the brain-computer interface industry into a new phase

    Zhitong·
    SH
    688273
    -2.48%
    SH
    688767
    +4.13%
    SZ
    301330
    -2.45%
    Zhitong·
    SH
    688273
    -2.48%
    SH
    688767
    +4.13%
    SZ
    301330
    -2.45%

    BIOTEST BIOTECH released its semi-annual performance, with a net profit attributable to the parent company of 12.4 million yuan, a year-on-year decrease of 82.82%

    According to the Zhitong Finance APP, BIOTEST BIOTECH disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 203 million yuan, a year-on-year decrease of 23.91%; net profit attributable to the parent company was 12.4 million yuan, a year-on-year decrease of 82.82%; net profit excluding non-recurring items was 6.83 million yuan, a year-on-year decrease of 90.25%; basic earnings per share were 0.07 yuan

    Zhitong·
    SH
    688767
    +4.13%
    Zhitong·
    SH
    688767
    +4.13%

    BIOTEST BIOTECH: Xu Ping plans to reduce her holdings by 3% starting in September

    BIOTEST BIOTECH announced that as of the date of this announcement, the actual controller, Xiu Ping, holds 24.9536 million shares of the company, accounting for 16.71%. Due to personal funding needs, he plans to reduce his holdings through centralized bidding by no more than 1.4933 million shares and through block trading by no more than 2.9867 million shares, totaling no more than 4.48 million shares, which is no more than 3%

    Zhitong·
    SH
    688767
    +4.13%
    Zhitong·
    SH
    688767
    +4.13%

    Gao Hongmei, a director of BIOTEST BIOTECH, completed a reduction in holdings, with a total reduction of 560,000 shares

    According to the Zhitong Finance APP, BIOTEST BIOTECH announced that the share reduction plan of the company's director and senior management Gao Hongmei has been completed, with a total of 560,000 shares sold through centralized bidding, accounting for 0.5250% of the company's total share capital

    Zhitong·
    SH
    688767
    +4.13%
    Zhitong·
    SH
    688767
    +4.13%

    BIOTEST BIOTECH: Wholly-owned subsidiary Botai Zhito strategically invests in Zhejiang University Brain-Machine Interface Achievement Transformation Project

    China's first closed-loop spinal cord nerve interface implantation surgery was successfully completed recently, attracting significant attention. The surgery was jointly performed by the Second Affiliated Hospital of Zhejiang University School of Medicine and the Nanhu Brain-Machine Intersection Research Institute. On the 20th, BIOTEST BIOTECH announced that it had invested in Qingshi Yongjun through BoTai ZhiTou and acquired a 5% equity stake. The latter was founded by the invasive brain-machine interface team from Zhejiang University and is the first technology transfer enterprise of the Nanhu Brain-Machine Intersection Research Institute

    Zhitong·
    SH
    688767
    +4.13%
    Zhitong·
    SH
    688767
    +4.13%